interessant, die Aussage eines Neurologen zu patient#3 - 500 Beiträge pro Seite

[Cyberhexe]

Do we know where patient #3 (CD) was hospitalized. I have heard #1 was Colorado and #2 was UCSF.

Neuropathology is tricky and not done frequently at many places. I`m wondering if the original path sample was reviewed by neuropathology or just pathology. As an example, where I trained, every brain biopsy sample was reviewed by neuropathologists, usually conferenced if interesting. Where I am now, all neuropathology is first read locally and most is then sent to a nearby academic center. At the AAN meeting, they mentioned that the pathology was reviewed in March by two independent neuropathologists who both agreed that the sample represented PML. I don`t know the identitites nor qualifications of these 2 neuropathologists. I also don`t know if they were asked for a diagnosis without mentioning PML or whether they were asked if the sample could be PML. I would think it would be the former as they would want a true second and third opinion. I also wonder if the MRIs were reviewed by neuroradiologists (or neurologists) or just radiologists.

At the AAN, they did mention that #3`s white blood cell counts were low. That side effect is much more likely to occur with azathioprine (in fact that`s how we dose it, by following WBC) than with Tysabri (where WBC counts stayu the same or increase). Either way, I think the azathioprine played a very major role and he was not washed out before restarting Tysabri the second time. Although, he was on `monotherapy` at time of diagnosis, he was still in the window of long term effects of azathioprine.

[Cyberhexe]

also ich gehe nun einmal davon aus, dass Patient#3 -derjenige aus der SENTINEL-Studie, der 2003 verstarb...und dessen Diagnose nachträglich in PML geändert wurde (ursprünglich Gehirntumor) - nicht der Monotherapie zugeordnet werden kann, da zum Zeitpunkt der fatalen Folgen die immunsuppressive Wirkung von Azathioprin noch andauerte.

[Cyberhexe]

meine Zuversicht wächst...zeni, das dürfte ein gutes Börsenjahr werden.

nice weekend
CH

[Cyberhexe]

sorry Patient#3 hat natürlich nicht an der SENTINEL- sondern an der ENACT2-Studie (MorbusCrohn) teilgenommen


DUBLIN, Ireland & CAMBRIDGE, Mass. & SAN DIEGO, Sep 29, 2004 (BUSINESS WIRE) -- Elan Corporation, plc and Biogen Idec today announced that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the approval of ANTEGREN(R) (natalizumab) as a treatment for Crohn`s disease. Additionally, the companies presented new 12-month data from the Phase III maintenance trial, ENACT-2 (Evaluation of Natalizumab As Continuous Therapy-2), today at the United European Gastroenterology Week meeting in Prague, Czech Republic, and these data were included in the filing.

[Cyberhexe]

die folgenden Zeilen sind die Quintessenz:

At the AAN, they did mention that #3`s white blood cell counts were low. That side effect is much more likely to occur with azathioprine (in fact that`s how we dose it, by following WBC) than with Tysabri (where WBC counts stayu the same or increase). Either way, I think the azathioprine played a very major role and he was not washed out before restarting Tysabri the second time. Although, he was on `monotherapy` at time of diagnosis, he was still in the window of long term effects of azathioprine.


also jetzt ist aber schluss
nice we
ch